Hadlima is a prescription medication (adalimumab-bwwd) and a biosimilar that supports treatment for certain chronic conditions. It is a therapy applied in addressing a range of chronic inflammatory conditions, **relevant in contexts involving heightened systemic burden.

Hadlima is commonly used to help with managing symptoms that interfere with daily comfort across several disease states. These include Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis, Crohn's disease, Ulcerative Colitis, Plaque Psoriasis, Hidradenitis Suppurativa, and Uveitis. The primary therapeutic domain is providing supportive relief for patients dealing with these chronic conditions.

This medication assists in addressing symptom clusters that may become intense or disruptive, used in settings marked by temporary physiological imbalance. It is relevant for easing symptoms related to physical discomfort in the joints and stiffness, and is applied in addressing irritative skin states and gastrointestinal discomfort.

“The medication contributes to improved comfort during periods of heightened symptoms.”

Quick Fact: Supports Management of Physical Discomfort

Regulatory References

1. Adalimumab Injection: MedlinePlus Drug Information

Who Can and Cannot Use Hadlima?

The official regulatory labeling defines patient eligibility based on age, acute health status, and pre-existing conditions.

Populations for Whom Use is Contraindicated

Treatment with Hadlima must not be started in patients who have an active severe infection, including active tuberculosis (TB) or sepsis. Use is also contraindicated for patients with moderate to severe heart failure (NYHA Class III/IV) and those with a history of serious hypersensitivity reaction to adalimumab or any product excipients.

Age-Related Eligibility Rules

Population	Approved Status (by Indication)
Adults	Approved for use in all indicated conditions.
Pediatric Patients	Minimum age thresholds apply: 2 years and older for Juvenile Idiopathic Arthritis and Uveitis; 6 years and older for Crohn’s disease.
Use Not Established	Children younger than 2 years are generally not studied, and use in patients with renal or hepatic impairment is not established in the label, meaning no dose recommendations can be made.

Eligibility-Related Restrictions

Patients with latent TB must begin appropriate treatment for the infection prior to initiating Hadlima. Caution and close monitoring are required for individuals with a history of chronic infections, Hepatitis B Virus (HBV) carriers, or certain neurological disorders like multiple sclerosis. Use during pregnancy is permitted only if the potential benefit justifies the potential risk to the fetus, as adequate studies are not available.

---

Connection to the overall eligibility profile

Regulatory documents establish patient eligibility for Hadlima by defining specific populations who are permitted to use it based on their age and diagnosis, alongside absolute contraindications that prohibit use due to underlying conditions like severe heart failure or active infection. Furthermore, the official label imposes specific restrictions for populations where data is insufficient, such as those with renal or hepatic impairment, or where pre-treatment (like for latent TB) is mandatory before the medicine can be started. This structured regulatory framework dictates who can and cannot use the medicine according to governmental approval.

Interactions with other medicines and products

Official Regulatory Statement on Prohibited Combinations

The interaction profile of Hadlima is primarily defined by pharmacodynamic restrictions outlined in regulatory labeling. The co-administration of Hadlima with certain medicinal products is contraindicated due to the officially documented risk of serious infection without added clinical benefit.

Interaction Classification	Interacting Substance/Class
Prohibited	Live Vaccines (risk of inducing infection)
Prohibited	Other Biologic DMARDs (e.g., Anakinra, Abatacept)

---

Documented Pharmacological Interaction Patterns

The regulatory profile highlights specific cautions concerning exposure modification and effects on the immune response.

• Exposure Modification: Co-administration with Methotrexate is officially documented to result in increased Hadlima exposure (lower apparent clearance and higher trough concentrations). This is a formal pharmacokinetic/pharmacodynamic finding.
• Vaccine Response: Concomitant use with non-live vaccines may result in a reduced immune response, officially noted as a limitation on vaccine efficacy.
• Metabolism and Food: As a large monoclonal antibody, Hadlima is degraded by catabolism, not metabolized by CYP450 enzymes. Official prescribing information documents no explicit interactions with CYP450 enzymes, drug transporters, food, or alcohol.

Hadlima (adalimumab-bwwd) is a monoclonal antibody that modulates the immune system. Its mechanism of action involves highly specific molecular binding, which leads to a cascade of physiological effects.

---

Targeted Cytokine Neutralization

Hadlima functions as a tumor necrosis factor (TNF) blocker. It binds with high affinity to both the soluble and transmembrane forms of TNF-alpha (TNFalpha). This action prevents the proinflammatory cytokine TNF-alpha from interacting with its specific receptors (TNFR1 and TNFR2) on cell surfaces, thereby disrupting proinflammatory signaling cascades.

---

Inflammatory Pathway Interruption

By neutralizing TNF-alpha, Hadlima interferes with the subsequent signaling cascades that would normally be triggered by receptor engagement. This primarily includes the disruption of pathways like NF-kappaB and MAPK, which decreases the transcription of genes encoding inflammatory mediators such as IL-1 and IL-6. This modification of early molecular steps shapes the overall cellular response.

---

Regulated Physiological State

The collective effect of inhibiting the TNF-alpha signaling network results in the modulation of activation and recruitment of various immune cells, including macrophages and T-cells, at local tissue sites. This promotes restored balance in pathway dynamics by modulating the duration and magnitude of mediator activity within targeted immune pathways.

Administration Overview

Hadlima is administered via subcutaneous injection, which means it is injected into the fatty tissue just beneath the skin. This medication is typically available in two forms: a prefilled syringe or a prefilled autoinjector.

Injection Sites

The recommended areas for injection include:

• The front of the thighs
• The abdomen (avoiding the area within two inches of the navel)

It is important to rotate the injection site with each dose to reduce the risk of skin irritation or soreness. New injections should be given at least one inch away from a previous site. Injections should not be administered into areas where the skin is tender, bruised, red, hard, or scarred.

Preparation

Before administration, the medication is usually removed from the refrigerator and allowed to reach room temperature. This process generally takes about 15 to 30 minutes. The medication should be protected from direct sunlight during this time.

The solution should be inspected through the viewing window of the device. It should appear clear and colorless to pale brown. If the liquid is cloudy, discolored, or contains large particles, the device should not be used.

Self-Administration

Patients or caregivers can perform the injections after receiving proper training from a healthcare professional. Training typically covers the aseptic technique required for preparation, the specific operation of the chosen delivery device (syringe or autoinjector), and the proper disposal of used materials.

Research Evidence / Overview of Studies for Hadlima

This overview describes the official research and clinical trials that form the foundation for Hadlima, focusing on the types of evidence regulators rely on. The evidence for Hadlima, an interchangeable biosimilar, primarily centers on comparative studies confirming its high similarity to the reference product (adalimumab), which establishes the foundation for the extrapolation of existing research findings from the active ingredient.

---

The Research Foundation for Hadlima's Use

Hadlima was studied for use in adults with Rheumatoid Arthritis (RA), a condition characterized by fluctuating or episodic manifestations, through rigorous comparative Phase 3 clinical trials. These studies evaluated the comparability of Hadlima against the reference product in adults with moderately to severely active RA. Research explored short-term symptom changes and measured outcomes related to physical discomfort using standardized clinical scoring systems. These studies monitored changes in joint symptom scores. Comparative studies described similar measured patterns between Hadlima and the reference drug over a defined time interval, which contributes to the broader evidence landscape for the active ingredient.

---

Evidence for Chronic Inflammatory Joint Conditions and Psoriasis

The primary comparative trial setting for Hadlima was for Rheumatoid Arthritis, as this condition was selected as the sensitive population to demonstrate biosimilarity. Here, short-term Randomized Controlled Trials (RCTs) were conducted during periods of increased symptom activity, and studies also monitored radiographic outcomes reflecting structural changes over time.

Research for Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), and Plaque Psoriasis was evaluated in the context of regulatory extrapolation. This means that because high similarity was established in the sensitive population, the extensive existing research on the active ingredient for these other conditions was considered in the regulatory decision. While the active ingredient has been studied extensively, Hadlima did not require separate comparative trials for each of these specific indications. Studies for these conditions measured outcomes reflecting daily functioning and scores related to skin clearance or spinal mobility.

---

Research Gaps and Remaining Uncertainties

There are acknowledged limitations in the research landscape. A key limitation is that comparative evidence is lacking for Hadlima in many approved indications (such as Crohn's Disease or Psoriasis), as these were approved via regulatory extrapolation from the RA comparative data. There is limited information for long-term outcomes specific to Hadlima, and certainty remains low regarding the full range of potential immunogenicity patterns over many years. Subgroup findings are uncertain for specific populations where only small sample sizes or limited research has been conducted. Studies help show what has been observed so far, but research does not determine whether an individual will respond similarly.

Key Studies & References NIH National Library of Medicine (NLM) MedlinePlus Drug Information: Adalimumab Injection

Common questions about Hadlima (FAQ)

Q: What is Hadlima used for besides rheumatoid arthritis?

Hadlima is approved for several chronic inflammatory conditions in addition to Rheumatoid Arthritis. According to official product information, these include Psoriatic Arthritis, Ankylosing Spondylitis, Crohn's Disease, Ulcerative Colitis, Plaque Psoriasis, Hidradenitis Suppurativa, Juvenile Idiopathic Arthritis, and Uveitis.

---

Q: Is Hadlima the same as Humira?

No. Hadlima is classified as an interchangeable biosimilar to the reference product Humira. This designation indicates that it is highly similar to Humira with no clinically meaningful differences in safety or effectiveness. An interchangeable biosimilar may be substituted for the reference product by a pharmacist, depending on state laws.

---

Q: Can I take Hadlima if I am pregnant or planning to be?

Official labeling states that use during pregnancy is allowed only if the potential benefit justifies the potential risk to the fetus. This is because adequate human studies are not available to fully establish the risk. Information regarding pregnancy should be discussed with a healthcare provider.

---

Q: Does Hadlima affect fertility in men or women?

Specific human data on the effects of Hadlima on fertility is not established in official labeling. However, non-clinical studies in animals did not indicate specific risks regarding fertility.

---

Q: Can I drink alcohol while I am using Hadlima?

Official prescribing information indicates there are no explicit interactions documented between the medicine and alcohol. Regulatory documents do not contain a specific warning against the consumption of alcohol while taking this medicine.

---

Q: Does Hadlima cause weight gain or loss?

Weight changes are not listed as a common side effect in clinical trials documented in official product information. However, sudden weight gain can be a sign of worsening heart failure. Heart failure is a serious condition associated with TNF blockers, and sudden weight changes are documented as requiring notification of a healthcare provider.

---

Q: Is it normal to feel tired after taking Hadlima?

Routine fatigue or tiredness is not listed as a common side effect in regulatory documents. However, official safety information indicates that unusual weakness or fatigue can be a symptom of more serious, rare conditions associated with TNF blockers, such as heart failure or blood disorders.

---

Q: What are the long-term effects of using Hadlima?

Long-term use of adalimumab products, including Hadlima, is associated with a risk of serious infections and malignancy (cancer). Official documents also note other potential long-term risks, such as the development of autoantibodies or a lupus-like syndrome.

---

Q: Why do some people need to switch from Humira to Hadlima?

Hadlima’s designation as an interchangeable biosimilar is the regulatory factor that facilitates switching. This designation is the regulatory requirement that allows substitution under state laws.

---

Q: What foods or supplements should I avoid when taking Hadlima?

You can generally eat and drink normally while using this medicine. However, because this type of medicine affects the immune system, regulatory safety information identifies certain foods known to carry bacteria as areas of caution, such as raw eggs, undercooked meats, unpasteurized dairy products, and soft or blue cheeses.

---

Q: Can Hadlima be used for conditions like multiple sclerosis?

No. Multiple sclerosis is not an approved indication for Hadlima. The official label also cautions that the drug has been associated with rare cases of new onset or worsening of demyelinating diseases, which include conditions like multiple sclerosis.

---

Q: Can Hadlima be used with other immunosuppressant drugs?

Co-administration with other biologic DMARDs (like anakinra or abatacept) or other TNF blockers is not recommended due to a potential increase in the risk of serious infection. However, Hadlima is sometimes used in combination with non-biologic immunosuppressants such as methotrexate.

---

Q: Are there research studies looking at Hadlima's use in other inflammatory diseases?

The research supporting Hadlima's approval focused on a core set of inflammatory diseases through clinical trials and regulatory extrapolation. Official regulatory documents do not typically detail studies of the medicine for unapproved inflammatory conditions.

---

Q: Is there information about Hadlima being studied in people with non-FDA approved conditions?

Official regulatory documentation focuses exclusively on the approved uses and related clinical trial data. Information regarding the study of the medicine in non-approved conditions is generally not included in the official prescribing information.

---

Q: How long does Hadlima stay in the body after stopping treatment?

The time required for the medicine to fully clear the body is related to its elimination half-life, which is approximately two weeks. As a result, detectable amounts of the medicine may remain in the body for several months after the last dose.

---

Q: Is it possible to develop a tolerance to Hadlima over time?

The regulatory term for a potential change in the body’s response to the medicine is immunogenicity. Official documents indicate that treatment with adalimumab products may result in the formation of autoantibodies over time, which can potentially lead to a reduced clinical response.

---

Q: What are the eligibility requirements for starting Hadlima?

Eligibility is defined by official labeling and is determined by having a specific approved condition (such as moderate to severe Rheumatoid Arthritis) and meeting other criteria. This often involves having had an inadequate response to or a contraindication for conventional therapies for the condition.

---

Q: Does Hadlima require a specific type of injection device?

Hadlima is supplied as a sterile solution in either a single-dose prefilled syringe or a single-dose autoinjector (PushTouch) device. These are the required administration methods defined in the official instructions for use.

---

Q: Are there different versions of Hadlima?

Yes. Hadlima is available in both a high-concentration formulation and a low-concentration formulation for different patient needs. Official labeling provides information on both versions.

---

Q: Is Hadlima a treatment for ankylosing spondylitis?

Yes. Hadlima is indicated for the treatment of active ankylosing spondylitis in adults. This is based on clinical data and regulatory approval.

---

Q: How does Hadlima work in simple terms?

Hadlima is classified as a Tumor Necrosis Factor (TNF) blocker. It works by targeting and neutralizing a specific protein in the body called TNF-alpha. This protein acts as a central messenger that drives the excessive and destructive inflammation seen in chronic diseases, allowing the medication to help regulate the body's inflammatory response.

---

Q: What makes Hadlima different from other adalimumab biosimilars?

While all adalimumab biosimilars are highly similar, they may differ in formulation and injection device. Hadlima is available as a citrate-free, high-concentration formulation. The citrate-free formulation has been developed with the intent of potentially reducing injection-site discomfort.

How to Store and Dispose of Hadlima (Adalimumab-bwwd)

Official regulatory guidelines strictly define the storage and disposal requirements for Hadlima.

Storage Requirement	Specification
Primary Temperature	Store in the refrigerator at 36 F to 46 F (2 C to 8 C).
Protection	Keep in the original carton to protect from light. Do not freeze.
Room Temperature Stability	If removed from refrigeration, it may be stored at a maximum of 77 F (25 C) for a single, non-reversible period of up to 14 days. Discard if not used within this time.
Handling Notes	Do not shake. Allow 15–30 minutes to warm naturally before injection; do not use external heat. Do not reuse.
Child Safety	Keep out of the sight and reach of children.
Disposal	Immediately place all used prefilled syringes or autoinjectors into an FDA-cleared, puncture-resistant sharps disposal container. Unused or expired medicine should be returned to a pharmacist for proper disposal according to local requirements. Do not throw used sharps in household trash.